@article {10.3844/ajptsp.2014.68.74,
article_type = {journal},
title = {RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW},
author = {Sunny, Anjo and Khan, M. Arif and Mahesh, Darpelly and Chauhan, Nikhil Singh and Mishra, Ritu and Presila, Namindla and Samuel, Asa},
volume = {9},
year = {2014},
month = {Feb},
pages = {68-74},
doi = {10.3844/ajptsp.2014.68.74},
url = {https://thescipub.com/abstract/ajptsp.2014.68.74},
abstract = {The purpose of this review is to give the readers an insight about the risks and benefits of ’quinapril’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, an attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day clinical practice.},
journal = {American Journal of Pharmacology and Toxicology},
publisher = {Science Publications}
}